胶质瘤中端粒酶逆转录酶启动子区突变分析及其预后意义

doi:10.3969/j.issn.1004-616x.2015.05.007

癌变·畸变·突变 ›› 2015, Vol. 27 ›› Issue (5): 361-365.doi: 10.3969/j.issn.1004-616x.2015.05.007

胶质瘤中端粒酶逆转录酶启动子区突变分析及其预后意义

何洁^1,2, 万经海², 李学记², 钱海鹏², 孟肖利², 郝佳洁³, 徐昕³, 王明荣³

1. 安徽医科大学第二附属医院神经外科, 安徽合肥 230601;
2. 中国医学科学院肿瘤医院神经外科, 北京 100021;
3. 中国医学科学院北京协和医学院肿瘤医院分子肿瘤学国家重点实验室, 北京 100021

收稿日期:2015-05-08 修回日期:2015-06-29 出版日期:2015-09-30 发布日期:2015-09-30
通讯作者: 万经海,E-mail:wanjinghai@sina.com E-mail:wanjinghai@sina.com
作者简介:何洁,E-mail:neuromedic@163.com。
基金资助:
国家自然科学基金项目(81470112)

TERT promoter mutation is a potential biomarker for predicting poor outcome in gliomas

HE Jie^1,2, WAN Jinghai², LI Xueji², QIAN Haipeng², MENG Xiaoli², HAO Jiajie³, XU Xin³, WANG Mingrong³

1. Department of Neurosurgery, the Second Hospital of Anhui Medical University, Hefei 230601, Anhui;
2. Department of Neurosurgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021;
3. State Key Laboratory of Molecular Oncology, Cancer Institute & Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing 100021, China

Received:2015-05-08 Revised:2015-06-29 Online:2015-09-30 Published:2015-09-30

摘要/Abstract

摘要：

目的:探讨端粒酶逆转录酶(TERT)启动子区突变与胶质瘤患者临床病理指标的关系及其对预后的影响。方法:应用Sanger测序技术检测78例脑胶质瘤组织中TERT启动子区C228T和C250T位点的突变情况,分析TERT启动子区突变与临床病理指标的关系及其对预后的影响。结果:TERT启动子区突变在脑胶质瘤中的发生率为32.1%,在低级别(Ⅰ~Ⅱ)和高级别(Ⅲ~Ⅳ)胶质瘤中突变分别占28.0%和34.0%。其中少突星形细胞瘤中突变占57.1%,胶质母细胞瘤中突变占44.4%,低级别星形细胞瘤和少突胶质细胞瘤中突变分别占28.6%和23.1%。TERT启动子区突变与胶质瘤患者术后生存时间显著相关,突变型术后生存时间显著短于野生型(P=0.001)。按低级别和高级别分组独立分析后发现,TERT启动子区突变在低级别组和高级别组中均与不良预后相关(P值分别为0.019和0.018)。Cox回归分析表明,TERT启动子区突变和术后放化疗是独立的预后影响因素(P=0.002,HR=3.486,95%CI: 1.591 ~7.637;P=0.004,HR=0.331,95%CI:0.156～0.699)。结论:TERT启动子区突变频繁发生于脑胶质瘤中,突变型胶质瘤患者预后不良。

关键词: 神经胶质瘤, 端粒酶逆转录酶, 启动子区突变, 预后

Abstract:

OBJECTIVE: To explore the correlation between TERT promoter mutations and clinicopathological features in patients with gliomas. METHODS:TERT promoter mutations were screened by direct DNA sequencing in a population-based collection of 78 glioma tissues. The correlation of TERT promoter mutations and the prognosis was analyzed. RESULTS:We identified TERT promoter mutations in 32.1% gliomas, including 28.0% in low grade tumors and 34.0% in high grade tumors. The mutations were much more common in oligoastrocytomas (57.1%) and glioblastomas (44.4%), while much less prevalent in astrocytomas (28.6%) and oligodendrogliomas(23.1%). Median overall survival of the patients harboring mutations in TERT promoter was longer than that without the mutations (P=0.001) in both low (P=0.019) and high grade gliomas (P=0.018). Multivariate analysis revealed TERT promoter mutations and no postoperative adjuvant therapy as significant prognostic factors for shorter survival (P=0.002, HR=3.486, 95%CI: 1.591-7.637;P=0.004, HR=0.331, 95%CI:0.156-0.699). CONCLUSION:TERT promoter mutations frequently occurred in gliomas, which was a prognostic factor of poor outcome for the patients with the same pathological grade gliomas.

Key words: gliomas, telomerase reverse transcriptase, promoter mutations, prognosis

中图分类号:

R739.41

何洁, 万经海, 李学记, 钱海鹏, 孟肖利, 郝佳洁, 徐昕, 王明荣. 胶质瘤中端粒酶逆转录酶启动子区突变分析及其预后意义[J]. 癌变·畸变·突变, 2015, 27(5): 361-365.

HE Jie, WAN Jinghai, LI Xueji, QIAN Haipeng, MENG Xiaoli, HAO Jiajie, XU Xin, WANG Mingrong. TERT promoter mutation is a potential biomarker for predicting poor outcome in gliomas[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(5): 361-365.

参考文献

[1] Ohgaki H. Epidemiology of brain tumors[J]. Methods Mol Biol,2009,472:323-342.

[2] Louis DN,Ohgaki H,Wiestler OD,et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol,2007,114(2):97-109.

[3] Killela PJ,Pirozzi CJ,Healy P,et al. Mutations in IDH1, IDH2,and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas[J]. Oncotarget,2014, 5(6):1515-1525.

[4] 李剑敏,万丽,黄卡特. 原发性与继发性胶质母细胞瘤中MGMT与突变型P53蛋白表达的差异及其生物学意义[J]. 癌变·畸变·突变,2009,(2):135-140.

[5] Huang FW,Hodis E,Xu MJ,et al. Highly recurrent TERT promoter mutations in human melanoma[J]. Science,2013, 339(6122):957-959.

[6] Horn S,Figl A,Rachakonda PS,et al. TERT promoter mutations in familial and sporadic melanoma[J]. Science, 2013,339(6122):959-961.

[7] Killela PJ,Reitman ZJ,Jiao Y,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal[J]. PNAS, 2013,110(15):6021-6026.

[8] Liu X,Bishop J,Shan Y,et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers[J]. Endocr Relat Cancer,2013,20(4):603-610.

[9] Rachakonda PS,Hosen I,de Verdier PJ,et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism [J]. PNAS,2013,110(43):17426-17431.

[10] Koelsche C,Sahm F,Capper D,et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system[J]. Acta Neuropathol,2013,126(6):907-915.

[11] Nonoguchi N,Ohta T,Oh JE,et al. TERT promoter mutations in primary and secondary glioblastomas[J]. Acta Neuropathol, 2013,126(6):931-937.

[12] Bojesen SE,Pooley KA,Johnatty SE,et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer[J]. Nat Genet,2013,45(4):371-384.

[13] Reitman ZJ,Pirozzi CJ,Yan H. Promoting a new brain tumor mutation:TERT promoter mutations in CNS tumors[J]. Acta Neuropathol,2013,126(6):789-792.

[14] Arita H,Narita Y,Fukushima S,et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss[J]. Acta Neuropathol,2013,126(2):267-276.

[1]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[2]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[3]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[4]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[5]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[6]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[7]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[8]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[9]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[10]	丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.
[11]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[12]	邵俊国, 焦文静, 王雪晓, 张金艳, 马鸣. miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 369-373.
[13]	吕燕萍, 吴传城, 杨双凤, 何陈周, 韩仁杰, 颜伟, 刘宝英. 胃癌差异表达miRNA及其相关基因的单核苷酸多态性与胃癌预后的相关性研究[J]. 癌变·畸变·突变, 2020, 32(5): 380-386.
[14]	郭秀娟, 杜彦艳, 颜晰, 赵学涛, 韩丽娜, 武一鹏, 王雪晓, 马鸣. CREB在食管鳞癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 387-390,394.
[15]	朱依青, 张彤彤, 郑珺文, 郝佳洁, 蔡岩, 王明荣, 梁建伟, 张钰. p-mTOR蛋白在结直肠癌组织中的表达及患者预后判断中的价值[J]. 癌变·畸变·突变, 2020, 32(3): 161-165.

胶质瘤中端粒酶逆转录酶启动子区突变分析及其预后意义

TERT promoter mutation is a potential biomarker for predicting poor outcome in gliomas

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价